Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	622.52	99.92	331.55	36.27	54	46.7
Short-Term Investments	436.55	534.22	27.23	234.08	230.15	392.35
Cash & Cash Equivalents	1,059	634.13	358.77	270.35	284.15	439.05
Cash Growth	221.44%	76.75%	32.71%	-4.86%	-35.28%	-9.24%
Inventory	0.85	0	0	0	0	0
Other Current Assets	14.04	3.15	2.6	1.34	1.01	1.15
Total Current Assets	1,074	637.28	361.37	271.68	285.16	440.2
Property, Plant & Equipment	3.33	3.27	1.2	1.65	1.83	1.86
Goodwill and Intangibles	5	0	0	0	0	0
Total Long-Term Assets	8.33	3.27	1.2	1.65	1.83	1.86
Total Assets	1,082	640.55	362.57	273.33	287	442.06
Accounts Payable	21.53	28.04	23.83	21.38	1.02	1.18
Current Debt	0.54	0.53	0.6	0.41	0.32	0.32
Other Current Liabilities	92.27	89.98	91.46	55.05	45.22	23.64
Total Current Liabilities	114.34	118.55	115.89	76.84	46.56	25.13
Long-Term Debt	117.18	116.67	49.29	0.39	0.47	0.36
Total Long-Term Liabilities	117.18	116.67	49.29	0.39	0.47	0.36
Total Liabilities	231.52	235.21	165.18	77.23	47.03	25.49
Total Debt	117.72	117.19	49.89	0.8	0.79	0.68
Debt Growth	39.12%	134.90%	6159.85%	1.40%	16.27%	-
Retained Earnings	-1,483.83	-1,336.29	-962.66	-667.31	-425.46	-223.22
Comprehensive Income	-0.17	0.47	-0.03	-0.08	0.05	0.22
Shareholders' Equity	850.76	405.33	197.39	196.11	239.97	416.57
Net Cash / Debt	941.34	516.94	308.88	269.55	283.36	438.37
Net Cash / Debt Growth	284.44%	67.36%	14.59%	-4.88%	-35.36%	-9.38%
Net Cash Per Share	47.06	27.66	18.02	16.30	18.34	28.48
Working Capital	959.61	518.73	245.48	194.85	238.61	415.07
Book Value Per Share	42.53	21.69	11.52	11.86	15.54	27.06

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).